Erin Hofstatter, MD
Associate Professor AdjunctCards
About
Research
Overview
Dr. Hofstatter serves as an academic breast cancer medical oncologist and Co-Director of the Smilow Cancer Genetics and Prevention Program at Yale, with a clinical specialty and research interest in breast cancer risk. Her clinical work includes seeing patients with breast cancer as well as patients at high risk of breast cancer due to a genetic mutation or other strong risk profile. Thus, her clinical work directly informs and inspires her research in breast cancer treatment and prevention. Since taking on the role of Co-Director of the Cancer Genetics and Prevention Program in 2014, she has successfully grown the clinical genetic counseling service to serve over 2000 patients per year, at multiple sites throughout the state of Connecticut. She has developed a robust clinical program that blends the services of genetic counselors and physicians, and has built a collaborative research program including a rich biorepository. In addition, Dr. Hofstatter serves as the Principal Investigator of several national cooperative group trials, including several trials for BRCA+ breast cancer, as well as her own investigator-initiated trials in DCIS and triple-negative breast cancer. She has developed skills in clinical trial design, survey development, epidemiology and biostatistics through her training and academic practice. Furthermore, Dr. Hofstatter has also developed skills in translational research, serving as Principal Investigator on a study examining epigenetic signatures of breast cancer risk and measures of aging in normal breast tissue.clinical breast cancer genetics
Medical Research Interests
Breast Neoplasms
Publications
2024
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.
Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, Lu A, Lucas N, Wu K, Shelton G, DeMerchant M, Lachowicz M, Kier M, Werner M, Eder J, Galsky M, Marron T, Smith C, LoRusso P, Hofstatter E, Doroshow D. Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials. JCO Oncology Practice 2024, op2400293. PMID: 39661920, DOI: 10.1200/op.24.00293.Peer-Reviewed Original ResearchEarly-phase clinical trialsSolid tumorsClinical trialsAssociated with higher FTFinancial toxicityBarriers to clinical trial enrollmentAdvanced solid malignanciesAdvanced solid tumorsInverse association with ageBaseline to 2 monthsYale Cancer CenterCOST scoreClinical trial enrollmentProspective survey studySolid malignanciesNo significant differenceBaseline FTTime of consentNovel therapiesPrimary outcomeCancer CenterSurvey 1Trial enrollmentPatientsEarly-phaseRare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history
Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Research And Treatment 2024, 1-6. PMID: 39602012, DOI: 10.1007/s10549-024-07560-y.Peer-Reviewed Original ResearchHigh-risk family historyFamily historyRare germline variantsCancer riskSNP-set kernel association testAssociated with breast cancer riskCancer casesContribution of family historyEarly-onset breast cancerCancer Prevention ClinicBreast cancerBreast cancer riskKernel association testBreast cancer casesCancer-predisposing genesGermline variantsGermline pathogenic variantsYoung womenPrevention clinicSKAT-OBurden testsPathogenic variantsExome sequencing dataAssociation TestLevel alterationsOvarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers
DiSilvestro J, Haddad J, Robison K, Beffa L, Laprise J, Scalia-Wilbur J, Raker C, Clark M, Lokich E, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers. Journal Of Women's Health 2024, 33: 624-628. PMID: 38488054, DOI: 10.1089/jwh.2023.0621.Peer-Reviewed Original ResearchRisk-reducing surgeryRisk-reducing strategiesMutation carriersGenetic testingIncreased screeningOvarian cancer risk reductionRisk of ovarian cancerRisk-reducing medicationsCancer risk reductionBRCA1/2 mutation carriersCross-sectional surveyOvarian cancerHigh-risk populationScreening utilizationEarly detection of ovarian cancerCombination of transvaginal ultrasoundCombined oral contraceptive pillDetection of ovarian cancerYears of ageSerum CA125 measurementOral contraceptive pillsFisher's exact testScreening protocolFemale participantsRisk reduction
2022
Financial toxicity in patients with advanced solid malignancies participating in early-phase clinical trials.
Blanter J, Werner M, Kier M, Hapanowicz O, Itani M, Ahmad M, DeMerchant M, Eder J, Galsky M, Hammad A, King P, Lachowicz M, Lucas N, Marron T, Shelton G, Wu K, Xu S, LoRusso P, Hofstatter E, Doroshow D. Financial toxicity in patients with advanced solid malignancies participating in early-phase clinical trials. Journal Of Clinical Oncology 2022, 40: 267-267. DOI: 10.1200/jco.2022.40.28_suppl.267.Peer-Reviewed Original ResearchOvarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383)
DiSilvestro J, Dexter J, Haddad J, Beffa L, Raker C, Laprise J, Wilbur J, Clark M, Bradford L, Brown A, Hofstatter E, Dalela D, Toland M, Robison K, Stuckey A. Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383). Gynecologic Oncology 2022, 166: s195-s196. DOI: 10.1016/s0090-8258(22)01605-5.Peer-Reviewed Original ResearchFemale BRCA mutation carriersOral contraceptive pillsOvarian cancer screeningBRCA mutation carriersOvarian cancerMutation carriersGenetic testingGynecologic oncologistsContraceptive pillsCancer screeningExact testBRCA 1/2 mutation carriersCombined oral contraceptive pillBRCA mutation typeRisk-reducing surgeryPrimary care providersHigh-risk populationHalf of womenBRCA1/2 mutation carriersPossible early detectionFisher's exact testCross-sectional surveyGenetic counselorsCA 125Surgical optionsThe Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients
Trant A, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients. Integrative Cancer Therapies 2022, 21: 15347354221137290. PMID: 36444764, PMCID: PMC9716631, DOI: 10.1177/15347354221137290.Peer-Reviewed Original ResearchConceptsTumor volumeBlack cohoshSitu patientsDuctal carcinomaAnti-inflammatory effectsTumor cellular proliferationBreast cancer treatmentCellular proliferationWilcoxon signed-rank testDCIS patientsAdverse eventsEligible subjectsWindow trialsCore biopsyInvasive diseaseKi67 expressionSigned-rank testBreast cancerGrade 3Hormone changesPatientsQuantitative immunofluorescenceBC extractSignificant toxicityCancer treatment
2021
Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.
Afghahi A, Marsh S, Winchester A, Gao D, Parris H, Axell L, Ellisen L, Hofstatter E, Kurian A, Wood M, Zakalik D, Mullin C, Caswell-Jin J, Borges V, Tung N. Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. Journal Of Clinical Oncology 2021, 39: 10531-10531. DOI: 10.1200/jco.2021.39.15_suppl.10531.Peer-Reviewed Original ResearchCHEK2 pathogenic variantsRecurrence scoreCase-control studyMedian RSBreast cancerPathogenic variantsHigh riskRisk groupsMutation statusHER2-negative BC patientsPR-negative breast cancerMulti-site case-control studyPatient-level clinical dataRS risk groupsLymph node statusHigh recurrence scoreLow-risk groupGermline pathogenic variantsSporadic breast cancerGenetic testing resultsElectronic medical recordsAdjuvant therapyChemotherapy benefitNode statusT stage
2020
Reproductive decision making and partnering in BRCA1/2 mutation carriers
DiSilvestro J, Haddad J, Robison K, Beffa L, Laprise J, Wilbur J, Raker C, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Reproductive decision making and partnering in BRCA1/2 mutation carriers. Gynecologic Oncology 2020, 159: 260-261. DOI: 10.1016/j.ygyno.2020.05.449.Peer-Reviewed Original ResearchBarriers to hormone replacement therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers
DiSilvestro J, Haddad J, Robison K, Beffa L, Laprise J, Wilbur J, Raker C, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Barriers to hormone replacement therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers. Gynecologic Oncology 2020, 159: 260. DOI: 10.1016/j.ygyno.2020.05.448.Peer-Reviewed Original Research
2019
Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.
Parkinson G, Chagpar A, Alleyne-Mike K, Nunez-Smith M, Zhou A, Servais L, Hofstatter E. Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Journal Of Clinical Oncology 2019, 37: 6574-6574. DOI: 10.1200/jco.2019.37.15_suppl.6574.Peer-Reviewed Original ResearchFemale breast cancer patientsBreast cancer patientsNCCN criteriaCancer patientsGenetic counselingHigher breast cancer mortality ratesYounger ageHBOC testingBreast cancer mortality ratesOvarian cancer syndromeBreast cancer treatmentBreast cancer casesCancer mortality ratesYears of ageTesting servicesFurther genetic counselingPre-test counselingBreast cancer diagnosisNCCN guidelinesChart reviewFemale patientsOncology unitBreast cancerCancer casesFamily history
Academic Achievements & Community Involvement
News & Links
News
- March 31, 2022
Research Reveals “Biologically Older” Tissue in Patients With Breast Cancer
- October 20, 2021
Internal Medicine News Roundup (10/20/21)
- September 30, 2020
Smilow Shares: HBOC Cancer Risks, Part 1
- September 23, 2020
Smilow Shares: Understanding Genetic Testing and Counseling